AXM Pharma Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and AXM Pharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days AXM Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable primary indicators, AXM Pharma is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Price Earnings Ratio | 0.0005 | |
| Total Cashflows From Investing Activities | -22.7 M |
AXM |
AXM Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in AXM Pharma on November 14, 2025 and sell it today you would earn a total of 100.00 from holding AXM Pharma or generate -100.0% return on investment over 90 days. AXM Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than AXM, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AXM Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AXM Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AXM Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AXM Pharma is not yet fully synchronised with the market data | |
| AXM Pharma has some characteristics of a very speculative penny stock | |
| AXM Pharma has a very high chance of going through financial distress in the upcoming years | |
| AXM Pharma currently holds 3.61 M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. AXM Pharma has a current ratio of 0.69, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AXM Pharma's use of debt, we should always consider it together with its cash and equity. |
AXM Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AXM Stock often depends not only on the future outlook of the current and potential AXM Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AXM Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 159 M | |
| Short Long Term Debt | 18.3 K |
AXM Pharma Fundamentals Growth
AXM Stock prices reflect investors' perceptions of the future prospects and financial health of AXM Pharma, and AXM Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AXM Stock performance.
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 28.73 M | |||
| Shares Outstanding | 10.41 B | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 113.08 M | |||
| EBITDA | (9.43 M) | |||
| Cash And Equivalents | 1.66 M | |||
| Total Debt | 3.61 M | |||
| Debt To Equity | 0.63 % | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | 34.76 M | |||
| Earnings Per Share | 0 X | |||
| Total Asset | 104.43 M | |||
| Retained Earnings | (34.77 M) | |||
| Current Liabilities | 14 K | |||
Things to note about AXM Pharma performance evaluation
Checking the ongoing alerts about AXM Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AXM Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AXM Pharma is not yet fully synchronised with the market data | |
| AXM Pharma has some characteristics of a very speculative penny stock | |
| AXM Pharma has a very high chance of going through financial distress in the upcoming years | |
| AXM Pharma currently holds 3.61 M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. AXM Pharma has a current ratio of 0.69, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AXM Pharma's use of debt, we should always consider it together with its cash and equity. |
- Analyzing AXM Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AXM Pharma's stock is overvalued or undervalued compared to its peers.
- Examining AXM Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AXM Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AXM Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AXM Pharma's stock. These opinions can provide insight into AXM Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in AXM Stock
If you are still planning to invest in AXM Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AXM Pharma's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |